DEPRICO 150
-
Chemical Name:
Trazodone HCl -
Therapeutic Category:
Central nervous system drugs -
Pharmacologic Category:
Antidepressant, Serotonin Reuptake Inhibitor/Antagonist -
Pharmaceutical Form:
Tablets -
Composition:
Trazodone HCl 150mg
DEPRICO
Tablets
Trazodone Hydrochloride
Anti-Depressant
1-PROPERTIES:
DEPRICO is a triazolopyridine (chlorophenyl - piperazine) antidepressant. It has a marked sedative action. It does not prevent the peripheral re-uptake of noradrenaline.
It has been shown to be a selective inhibitor of central serotonin uptake and to decrease peripheral serotonin uptake. It also appears to increase the turn-over of brain dopamine.
2-INDICATIONS:
DEPRICO is indicated for the treatment of depression with and without prominent anxiety.
3-CONTRAINDICATIONS:
DEPRICO is contraindicated in patients with:
- Hypertension.
- Cardiac disease.
- Pregnancy.
4-PRECAUTIONS:
- The possibility to suicide in seriously depressed patients is inherent in the illness and may persist until significant remission occurs.
- Prescriptions should be written for the smallest number of tablets consistent with good patient management.
- Orthostatic hypotension has been reported to occur in some patients receiving DEPRICO.
- DEPRICO should be used with caution in patients with epilepsy or hepatic or renal insufficiency.
- Patients receiving DEPRICO, if affected by drowsiness should not drive or operate machinery.
- DEPRICO should not be used in breast feeding mothers.
5-SIDE EFFECTS:
DEPRICO may cause: Sedation, blurred vision, vertigo, dry mouth, constipation, nausea, sweating, micturition, skin rashes, weight loss.
6-DRUG INTERACTIONS:
- Increased serum Digoxin or Phenytoin levels have been reported to occur in patients receiving DEPRICO concurrently with either of those two drugs.
- Concomitant administration of antihypertensive therapy may decrease the serum level of antihypertensive drug.
- Concurrent administration with electroshock therapy should be avoided because of the absence of experience in this area.
- There have been reports of increased and decreased prothrombin time.
- The sedative effects of DEPRICO may be enhanced by concurrent administration with alcohol or other central nervous system depressants.
- DEPRICO should not be given to patients receiving monoamine oxidase inhibitors.
7-DOSAGE & ADMINISTRAION:
The dosage should be initiated at a low level and increased gradually noting the clinical response.
Usual Adult Dosage: An initial dose of 50 mg/day, every 3 to 4 days. The dose may be increased up to 150 mg/day in divided doses (3 tablets 50 mg or 1 tablet 150 mg).
The Maximum Dose should not exceed: 400 mg/day in divided doses (or 8 tablets 50 mg or 2.5 tablets 150 mg).
In Extreme Cases: up to 600 mg/day in divided doses (12 tablets 50 mg or 4 tablets 150 mg).
In Elderly: 100 mg/day, and Maximum Dose : 300 mg/day
8-PACKAGING & COMPOSITION:
DEPRICO 50 - Tablets: A pack of 30 tablets. Each contains Trazodone HCl 50 mg.
DEPRICO 150 - Tablets: A pack of 30 tablets. Each contains Trazodone HCl 150 mg.
9-STORAGE CONDITIONS:
Store DEPRICO - Tablets at temperature between (15-30)°C. Protect from light.
Related Products
